ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HSCS vs RGNT // EV/EBITDA & P/E VALUATION

HeartSciences Inc. (NASDAQ) VS. Regentis Biomaterials Ltd. (NYSE) • 15-METRIC TALLY: HSCS 3 — RGNT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HSCS VS. RGNT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HSCS RGNT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 59.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -14.39% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -0.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 HSCS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.7 38.2 +9.49 HSCS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $17.5M $9.6M $7.9M HSCS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HSCS REV RGNT REV HSCS GROSS % RGNT GROSS % HSCS FCF RGNT FCF
FY 2025 $4.3K $0 59.1% — -$7.4M -$1.4M
FY 2024 $4.3K $0 56.8% — -$7.4M -$641.0K
FY 2023 $18.6K $0 — — -$6.1M -$1.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HSCS // BETA —
RGNT // BETA —